

A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immunotherapy

Samuel G. Awuah,[†] Yao-Rong Zheng,[†] Peter M. Bruno,[‡] Michael T. Hemann,[‡] and Stephen J. Lippard^{*,†,‡}

[†]Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

[‡]The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

S Supporting Information

ABSTRACT: Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance. IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clinical trials. IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics. Here we investigate Pt(IV)-(D)-1-methyltryptophan conjugates **1** and **2** for combined immunomodulation and DNA cross-link-triggered apoptosis for cancer “immuno-chemotherapy”. Compound **2** effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine production and promotes T-cell proliferation. Additionally, **1** and **2** display low toxicity in mice and are stable in blood. To our knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.

Attractive immunotherapy approaches have included chimeric antigen receptor (CAR) T-cell therapies, cancer vaccines, dendritic cell therapies, and immune checkpoint inhibitors.¹ Immune checkpoint therapy has become a clinically viable treatment alternative to conventional chemotherapy for cancer following the FDA approval of ipilimumab, pembrolizumab, and nivolumab.² Several immune checkpoints are involved in tumor immune escape with varied biological functions, signaling pathways, and expression levels in tumors.³ Programmed death (PD-1), cytotoxic T-lymphocyte antigen (CTLA), T-cell immunoglobulin and mucin 3 domain (TIM3),⁴ and IDO are common inhibitory immune checkpoint targets under investigation. Immune checkpoint therapy targets regulatory pathways that affect T-cells to enhance antitumor immune responses.⁵ Combining this therapy, by using small-molecule immune checkpoint inhibitors, with standard chemotherapy is likely to provide survival benefit to patients.

IDO is a heme-containing oxidoreductase encoded by the *INDO* gene. IDO catalyzes the degradation of the essential amino acid tryptophan to kynurenine with the exception of dietary tryptophan, which is catabolized by the liver enzyme tryptophan dioxygenase.⁶ The depletion of tryptophan mediates immune tolerance by suppressing effector T-cell function through G1

arrest and subsequent inactivation.⁷ In a variety of human tumors and host antigen-presenting cells, elevated levels of IDO are characteristic of poor prognosis.⁸ Small-molecule inhibitors of IDO that stimulate antitumor immunity have emerged, with (D)-1-methyltryptophan ((D)-1-MT, see Figure 1)⁹ and INCB-




Figure 1. Structures of key compounds under investigation.

24367^{1c} in Phase I/II clinical trials for the treatment of breast, brain, melanoma, and pancreatic cancers. Promising IDO inhibitors with unique chemical scaffolds continue to attract attention; among them are brassinins, quinones, phenylimidazoles, and hydroxyamidines.¹⁰ These small molecules have the advantages of being (i) easy to produce and deliver, (ii) inexpensive, and (iii) compatible with conventional cancer therapies.

IDO inhibitors enhance the efficacy of common chemotherapeutics¹¹ and are synergistic with radiation therapy.¹² The IDO inhibitor methylthiohydantoin-tryptophan in combination with cisplatin regresses autochthonous murine breast tumors.¹¹ Induction of IDO-blockade using (D)-1-MT and NLG919 works synergistically with temozolomide, cyclophosphamide, and radiotherapy to treat GL261 tumors (glioblastoma)¹³ in a syngeneic mouse model. Combination chemotherapy incorporating IDO inhibitors holds promise for cancer therapy. A dual-

Received: September 28, 2015

Published: November 12, 2015

threat construct¹⁴ having a potent chemotherapeutic and immune checkpoint inhibitor has thus far not been reported.

Platinum-based chemotherapy is first-line treatment for many cancers in the clinic.¹⁵ FDA-approved Pt agents include cisplatin, carboplatin, and oxaliplatin. They induce apoptosis in cancer cells, primarily through DNA damage.¹⁶ Despite the efficacy of Pt drugs, toxicity, tumor recurrence, acquired and inherent resistance, and deactivation are associated drawbacks that remain problematic.¹⁷ To overcome these problems, one chemical strategy that we and others have employed has been to design an inert Pt(IV) prodrug that can be activated by intracellular reduction following cellular uptake. Given the aforementioned limitations of conventional chemotherapy and immunotherapy, and taking advantage of the potential synergy between Pt drugs and immune checkpoint inhibitors, we employed the Pt(IV) prodrug strategy to combine immunomodulation with Pt–DNA cross-linking-induced apoptosis, affording the first effective immuno-chemotherapeutic.

A symmetric manifestation of our design attaches two (D)-1-MT units at the axial positions of a cisplatin pro-drug (**1**, Figure 1). An asymmetric construct having a hexadecyl hydrophobic chain at one axial position and (D)-1-MT at the other was also prepared (**2**, Figure 1). The latter synthetic strategy provides a unique double prodrug, activated by both intracellular reduction and esterase activity. The use of the long hydrophobic chain was motivated by our earlier report showing Pt(IV) binding to human serum albumin (HSA) for drug delivery.¹⁸ Detailed chemical studies revealed that **2** binds HSA, as evidenced in Figure S1 by FPLC, graphite furnace atomic absorption spectrophotometry (GFAAS), and ESI-MS analysis. Furthermore, the degree of lipophilicity of (D)-1-MT, **1**, and **2** was determined by measuring the extent of compound partition between octanol and water, $P_{o/w}$. Experimentally determined Log P values, shown in Table S1, increase from (D)-1-MT (Log P = -2.98 ± 0.15) to **1** (Log P = -0.21 ± 0.08) to **2** (Log P = 1.35 ± 0.26), which determines their cellular differential uptake. We hypothesized that release of (D)-1-MT from **1** or **2** inside cancer cells would block IDO to prevent T-cell degradation, while generation of cisplatin would concomitantly induce DNA damage-induced cell death. A thorough investigation of this novel, dual-threat prodrug approach provided the results presented here, including the synthesis and characterization, cellular mechanism, functional IDO inhibition, and cellular immunomodulation of **1** and **2**. The potent anti-proliferative ability of the constructs, nanoparticle formulation, and stability in mice were also investigated.

Compounds **1** and **2** were prepared and characterized as outlined in Scheme S1 (Supporting Information, see also Figures S2–S9) and tested against a panel of human ovarian cancer cells with varying sensitivities to cisplatin and constitutive expression of IDO. We found that SKOV3 cells constitutively express robust levels of IDO, A2780 cells express the protein minimally, and NIH:OVCAR3 not at all (Figure S10). The conversion of tryptophan to kynurenine by IDO suppresses the antitumor immune response.⁷ We therefore investigated the ability of **1** and **2** to block kynurenine production in cells. With the use of HPLC (Figure S11), we observed that **2** blocks kynurenine release in the medium of SKOV3 cultured cells by a factor of 3 in comparison to treatment with (D)-1-MT (Figure 2A). Using immunoblotting and qRT-PCR, we found that **2** selectively targets and effectively blocks IDO protein expression (Figure 2B), whereas **1** requires a 10-fold higher concentration (100 μ M, see Figures S12 and S13). Previously we demonstrated that cisplatin–DNA adducts block transcription, ultimately triggering apoptosis.¹⁹ However, inves-




Figure 2. (A) Kynurenine inhibition by **2** (10 μ M) in comparison to (D)-1-MT (1 mM) and an untreated control. (B) Immunoblotting of the pharmacological inhibition of human IDO in SKOV3 cells. Cells were treated with 10 μ M Pt for **1**, **2**, and C₁₆-Pt-Suc.

tigation of the control platinum construct C₁₆-Pt-Suc did not show IDO inhibition relative to **2** (Figure 2B). This result indicates that Pt–DNA adducts do not block IDO transcription or induce IDO mRNA instability, but (D)-1-MT released in the cells does. Collectively, our findings demonstrate the ability of **2** to interrupt the kynurenine pathway by depleting IDO.

The ability of **1**, **2**, and cisplatin as a control to promote cell death was evaluated by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay across a panel of human ovarian cancer cells. The concentration required for inducing 50% cell kill (IC₅₀) ranged from high nanomolar to micromolar, as extrapolated from dose–response curves; the results are summarized in Table S2. Significantly, complex **2** was the most potent, with no cross-resistance with cisplatin, as typified by its ability to induce cell death in both cisplatin-sensitive and -resistant ovarian cancer cell lines A2780 and A2780/CP70, SKOV3, and NIH:OVCAR3. Encouragingly, **2** displayed ~2–4000-fold potency in IDO-expressing cells, A2780 and SKOV3 over cisplatin, co-incubated [cisplatin+D-1MT], and C₁₆-Pt-Suc-NHC₂H₄OH-treated cells (Table S2).

The intracellular behavior of the Pt(IV)-(D)-1-MT construct (**2**) was analyzed by using an RNA interference (RNAi) methodology and cell cycle analysis.²⁰ This mechanism of action predictive RNAi methodology uses lymphoma cells that are partially infected with one of eight green fluorescent protein (GFP)-labeled short hairpin RNAs (shRNAs). Each shRNA has the potential ability to confer resistance or sensitivity to a particular drug, depending on its mechanism of action. Thus, after treatment with the drugs of interest, the cells are subjected to flow cytometry to assess GFP percentage. The resulting pattern of resistance and sensitivity to a given drug is then processed by a probabilistic K-nearest neighbors algorithm that assigns novel compounds to a category by comparing their signatures to that of a reference set of drugs. The RNAi signatures of cisplatin, *cis,cis,trans*-[Pt(NH₃)₂Cl₂(OCOCH₃)₂] (diacetate Pt(IV)), and **2** were obtained. Interestingly, although **2** displays features of a DNA-damaging agent, such as strong p53 and Chk2 shRNA enrichment, it differs significantly in other shRNAs, as shown in Figure 3A. In addition, DNA content assessment by flow cytometry revealed that **2** induces a cell cycle block at G1 phase in a time-dependent fashion (Figure S14), which deviates from the behavior of the classical G2/M arrest phase imposed by cisplatin (Figure S15). The collective evidence from both RNAi signature assays and cell cycle analysis indicates a unique mechanism of action triggered by the activity of (D)-1-MT provided by the construct (Figure 3B).

The ability of **2** to induce DNA damage was investigated by monitoring changes in expression of markers of the damage response pathway by immunoblotting analyses (Figures S16 and S17). SKOV3 cells incubated with **2** for up to 48 and 72 h showed a marked time-dependent increase in expression of phos-




Figure 3. (A) RNAi signatures derived from the treatment of E μ -Myc lymphoma cells with **2**, cisplatin, and diacetate Pt(IV) at LD_{80–90} for each compound after 72 h. (B) Principal component analysis plot of the RNAi signatures obtained from (A) and a reference set of drugs to elucidate the mechanism of action of complex **2**.

phorylated ATR, ATM, BRCA1, Chk1, Chk2, H2AX, and p53, indicative of DNA damage. Notably, the high phosphoBRCA1 response confirms the DNA damage role of BRCA1 specific to ovarian and breast cancer.

To gain further insight into the mode of action of **1** and **2**, we studied the subcellular distribution of Pt. SKOV3 cells were incubated with the drug candidates (5 μ M) for 17 h, using cisplatin as a control. The Pt content was measured by using GFAAS. Whereas the Pt content within the nucleus following **2** treatment was comparable to that of cisplatin, it was 7-fold higher in the cytoplasm (Figure S18). This result indicates that, over the duration of the study, **2** is preferentially taken up over both **1** and cisplatin, possibly due to its lipophilic axial chain. In addition, DNA platination studies shown in Figure S19 reveal the occurrence of 310 ± 75 Pt adducts/ 10^4 nucleotides for **1**, 409 ± 54 Pt adducts/ 10^4 nucleotides for cisplatin, and 970 ± 110 Pt adducts/ 10^4 nucleotides for **2**. These results demonstrate that, like cisplatin, the new Pt constructs target genomic DNA.

Mechanistic studies of the effect of **2** on the IDO pathway were performed by examining the autocrine-signaling loop of IDO-AHR-IL6 (Figure S20). The activation of AHR, a cytosolic transcription factor that translocates to the nucleus upon binding xenobiotic ligands such as kynurenine, is involved in tumor formation.²¹ The signal transducer and activator of transcription STAT3 mediates the process of carcinogenesis.²² We hypothesized that **2**, after spontaneous intracellular reduction and esterase activation, releases D-1MT into the cytosol to block IDO, leading to inactivation of AHR owing to kynurenine inhibition. Recent findings show that interleukin 6 (IL-6) modulates IDO expression via STAT3.²³ To support this hypothesis, SKOV3 cells were treated with **2**, and the RNA was harvested after 24 h for qPCR. The results show that mRNA expression levels of AHR decreased by 5-fold (Figure S21), and those of IL-6 were reduced by 10-fold (Figure S22) relative to untreated controls. These results support the role of **2** to interrupt the IDO pathway by deactivating the downstream AHR and IL-6, thereby destabilizing the autocrine loop implicated in constitutive IDO expression.

To target a key component of the immunosuppression-promoting IDO-AHR-IL6 loop, we investigated the immunomodulatory phenotype of **2**. A mixed leukocyte reaction (MLR)

was carried out. In this experiment, suspended 2×10^5 peripheral blood mononuclear cells (PBMCs) stimulated with phytohemagglutinin, and 2×10^5 cells of PBMCs from unrelated healthy donors as responders stained with carboxyfluorescein succinimidyl ester (CFSE), a cell-permeable fluorescent dye that binds amine residues (mostly lysines) covalently through its succinimidyl ester group, were co-cultured with adherent SKOV-3 (2000 cells). After 6 days of culture, PBMCs were harvested by centrifugation of medium and stained with APC-anti CD3, and T-cell proliferation was assessed by flow cytometry. T-cells express CD3, a cell surface multimeric protein complex involved in T-cell development and activation. PBMCs used were CD3^{high} as assessed by flow cytometry using APC-labeled anti-CD3 (Figure 4A). Consistent with our results of a decrease in




Figure 4. (A) Estimation of T-cell population in PBMCs by measuring CD3 cell surface marker using flow cytometry. (B) Mixed leukocyte reaction to assess T-cell proliferation induced by **2** (10 μ M) after 6 days of compound incubation with PBMCs and SKOV3 cells. T-cell division accounts for multiple generations (bands) measured by the intensity of CFSE dilution using flow cytometry.

kynurenine production by **2** due to downregulation of IDO and its downstream targets, the presence of **2** in the SKOV3/MLR coculture experiment resulted in the enhancement of alloreactive T-cell proliferation as assessed by live-cell tracing for multiple generations using flow cytometry (Figure 4B). Collectively, our cellular data show that **2** plays a role in immunomodulation, which results in T-cell proliferation.

Therapeutic nanoparticles (NPs) have been widely investigated for their potential to enhance cancer treatment.²⁴ The chemical structure of **2** bears both hydrophilic ((D)-1-MT) and hydrophobic (hexadecyl isocyanate) axial ligands, conferring amphiphilic character to the molecule. Work in our laboratory has shown that the hexadecyl isocyanate axial ligand facilitates non-covalent binding to HSA, protecting the Pt(IV) center from premature reduction in blood.¹⁸ In the presence of the biodegradable block copolymer, poly(lactic-co-glycolic acid)-polyethylene glycol (PLGA-PEG), **2** readily self-assembles into NPs suitable for preclinical studies (Figure 5A). Characterization of the NPs using DLS showed sizes of 120 ± 3.50 nm, applicable for preclinical studies (Figure S23). Having obtained the NPs, we proceeded to investigate the ability of **2** and its NP to induce apoptosis. Translocation of phosphatidylserine residues to the exterior is a characteristic of apoptotic cells, which have a compromised cell membrane, and can be detected by annexin V.²⁵ Using a dual staining annexin V/sytox green apoptosis dead cell assay, we examined the apoptotic behavior of SKOV3 cells




Figure 5. (A) Schematic representation of PLGA–PEG nanoparticles used to encapsulate **2**. (B) Time-dependent stability of **2** in mice treated with **2-NP** (8 mg/kg).

after 72 h of treatment with **2** and its NP by flow cytometry. Both **2** and its NP induced large populations of SKOV3 cells to undergo apoptosis, with the NPs doing so severely (Figure S24).

In vivo evaluation of **2** revealed that mice are tolerant of the Pt–immune checkpoint inhibitor conjugates. Dynamic blood stability experiments of **2** in 6-week old female Balb/c mice revealed $t_{1/2} \approx 1$ h (Figure 5B). Mice were intravenously injected with a sterile NP formulation of **2** at a relatively high dose of 8 mg/kg, and blood was drawn at different time intervals (10 min, 1 h, 3 h, 6 h, and 24 h). The hydrophobic complex **2** was extracted with octanol¹⁸ and diluted, and the Pt concentration was determined by GFAAS. By 24 h, the Pt concentration reached non-detectable levels, suggesting complete reduction of hydrophobic Pt(IV) to hydrophilic Pt(II) species. In addition, a human blood stability study showed $t_{1/2} = 2.2$ h for **2**, compared with those reported for cisplatin ($t_{1/2} = 21.6$ min)²⁶ and satraplatin ($t_{1/2} = 6$ min)²⁷ (see Figure S25).

In conclusion, we present a Pt–small-molecule immune checkpoint inhibitor platform that preferentially targets the immunosuppressive enzyme IDO to enhance T-cell proliferation. We investigated the synergy of Pt and checkpoint inhibitor biology as well as the molecular mechanism of (D)-1-MT. Our cellular data provide evidence for DNA damage induced by **2**, which leads to G1 arrest and cell death. Furthermore, IDO is inhibited to evoke downregulation of AHR and IL-6, which are key genes involved in the auto-regulation of constitutive IDO expression. This action leads to immunomodulation and enhanced T-cell proliferation. Work is currently underway to evaluate the in vivo tumor efficacy of this and other Pt–immune checkpoint inhibitors in immunocompetent mice. We foresee that this molecular design has the potential to facilitate discovery of metal-based small-molecule immunomodulators in targeting cancer cells by immuno-chemotherapy.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.5b10182.

Experimental details, characterization of compounds **1** and **2**, and data regarding all molecular biology, cellular, mice, and blood stability studies (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*lippard@mit.edu

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work is supported by the NCI under grant CA034992.

■ REFERENCES

- (1) (a) Couzin-Frankel, J. *Science* **2013**, *342*, 1432. (b) Kim, M. S.; Ma, J. S.; Yun, H.; Cao, Y.; Kim, J. Y.; Chi, V.; Wang, D.; Woods, A.; Sherwood, L.; Caballero, D.; Gonzalez, J.; Schultz, P. G.; Young, T. S.; Kim, C. H. *J. Am. Chem. Soc.* **2015**, *137*, 2832. (c) BioMedTracker. *Cancer Immunotherapies*, **2014**.
- (2) Sharma, P.; Allison, J. P. *Science* **2015**, *348*, 56.
- (3) Muller, A. J.; Scherle, P. A. *Nat. Rev. Cancer* **2006**, *6*, 613.
- (4) Kane, L. P. *J. Immunol.* **2010**, *184*, 2743.
- (5) Sharma, P.; Allison, J. P. *Cell* **2015**, *161*, 205.
- (6) Mellor, A. L.; Munn, D. H. *Nat. Rev. Immunol.* **2004**, *4*, 762.
- (7) Munn, D. H.; Shafizadeh, E.; Attwood, J. T.; Bondarev, I.; Pashine, A.; Mellor, A. L. *J. Exp. Med.* **1999**, *189*, 1363.
- (8) (a) Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B. J. *Nat. Med.* **2003**, *9*, 1269. (b) Okamoto, A.; Nikaido, T.; Ochiai, K.; Takakura, S.; Saito, M.; Aoki, Y.; Ishii, N.; Yanai, N.; Yamada, K.; Takikawa, O.; Kawaguchi, R.; Isonishi, S.; Tanaka, T.; Urashima, M. *Clin. Cancer Res.* **2005**, *11*, 6030. (c) Brandacher, G.; Perathoner, A.; Ladurner, R.; Schneeberger, S.; Obrist, P.; Winkler, C.; Werner, E. R.; Werner-Felmayer, G.; Weiss, H. G.; Gobel, G.; Margreiter, R.; Konigsrainer, A.; Fuchs, D.; Amberger, A. *Clin. Cancer Res.* **2006**, *12*, 1144.
- (9) (a) Munn, D. H.; Sharma, M. D.; Lee, J. R.; Jhaver, K. G.; Johnson, T. S.; Keskin, D. B.; Marshall, B.; Chandler, P.; Antonia, S. J.; Burgess, R.; Slingluff, C. L., Jr.; Mellor, A. L. *Science* **2002**, *297*, 1867. (b) Godin-Ethier, J.; Hanafi, L. A.; Piccirillo, C. A.; Lapointe, R. *Clin. Cancer Res.* **2011**, *17*, 6985.
- (10) Jiang, T.; Sun, Y.; Yin, Z.; Feng, S.; Sun, L.; Li, Z. *Future Med. Chem.* **2015**, *7*, 185.
- (11) Muller, A. J.; DuHadaway, J. B.; Donover, P. S.; Sutanto-Ward, E.; Prendergast, G. C. *Nat. Med.* **2005**, *11*, 312.
- (12) Hou, D. Y.; Muller, A. J.; Sharma, M. D.; DuHadaway, J.; Banerjee, T.; Johnson, M.; Mellor, A. L.; Prendergast, G. C.; Munn, D. H. *Cancer Res.* **2007**, *67*, 792.
- (13) Li, M.; Bolduc, A. R.; Hoda, M. N.; Gamble, D. N.; Dolisca, S. B.; Bolduc, A. K.; Hoang, K.; Ashley, C.; McCall, D.; Rojiani, A. M.; Maria, B. L.; Rixe, O.; MacDonald, T. J.; Heeger, P. S.; Mellor, A. L.; Munn, D. H.; Johnson, T. S. *J. Immunother. Cancer* **2014**, *2*, 21.
- (14) Dhar, S.; Lippard, S. J. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 22199.
- (15) Galanski, M.; Jakupec, M. A.; Keppler, B. K. *Curr. Med. Chem.* **2005**, *12*, 2075.
- (16) Wang, D.; Lippard, S. J. *Nat. Rev. Drug Discov.* **2005**, *4*, 307.
- (17) Siddik, Z. H. *Oncogene* **2003**, *22*, 7265.
- (18) Zheng, Y. R.; Suntharalingam, K.; Johnstone, T. C.; Yoo, H.; Lin, W.; Brooks, J. G.; Lippard, S. J. *J. Am. Chem. Soc.* **2014**, *136*, 8790.
- (19) Todd, R. C.; Lippard, S. J. *Metallomics* **2009**, *1*, 280.
- (20) (a) Jiang, H.; Pritchard, J. R.; Williams, R. T.; Lauffenburger, D. A.; Hemann, M. T. *Nat. Chem. Biol.* **2011**, *7*, 92. (b) Pritchard, J. R.; Bruno, P. M.; Gilbert, L. A.; Capron, K. L.; Lauffenburger, D. A.; Hemann, M. T. *Proc. Natl. Acad. Sci. U.S.A.* **2013**, *110*, E170. (c) Pritchard, J. R.; Bruno, P. M.; Hemann, M. T.; Lauffenburger, D. A. *Mol. BioSyst.* **2013**, *9*, 1604.
- (21) Opitz, C. A.; Litzenburger, U. M.; Sahm, F.; Ott, M.; Tritschler, I.; Trump, S.; Schumacher, T.; Jestaedt, L.; Schrenk, D.; Weller, M.; Jugold, M.; Guillemin, G. J.; Miller, C. L.; Lutz, C.; Radwimmer, B.; Lehmann, I.; von Deimling, A.; Wick, W.; Platten, M. *Nature* **2011**, *478*, 197.
- (22) Yu, H.; Pardoll, D.; Jove, R. *Nat. Rev. Cancer* **2009**, *9*, 798.
- (23) Litzenburger, U. M.; Opitz, C. A.; Sahm, F.; Rauschenbach, K. J.; Trump, S.; Winter, M.; Ott, M.; Ochs, K.; Lutz, C.; Liu, X.; Anastasov, N.; Lehmann, I.; Hofer, T.; von Deimling, A.; Wick, W.; Platten, M. *Oncotarget* **2014**, *5*, 1038.
- (24) Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. *Nat. Nanotechnol.* **2007**, *2*, 751.
- (25) Quinn, P. J. *Subcell. Biochem.* **2002**, *36*, 39.
- (26) Erdlenbruch, B.; Nier, M.; Kern, W.; Hiddemann, W.; Pekrun, A.; Lakomek, M. *Eur. J. Clin. Pharmacol.* **2001**, *57*, 393.
- (27) Carr, J. L.; Tingle, M. D.; McKeage, M. J. *Cancer Chemother. Pharmacol.* **2002**, *50*, 9.